Additionally, targeted therapies such as osimertinib for patients with epidermal growth factor receptor (EGFR) mutations have further advanced the field, marking a significant shift toward personalized medicine in the management of early-stage NSCLC [13,14]. Here, EGFR is linked to non-small cell lung carcinoma.